Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

ClinicalTrials.gov ID: NCT06414954

Public ClinicalTrials.gov record NCT06414954. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

Study identification

NCT ID: NCT06414954
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: NMD Pharma A/S; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Interventions

NMD670 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 15, 2024
Primary completion: Nov 30, 2026
Completion: Nov 30, 2026
Last update posted: Aug 20, 2026

2024 – 2026

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
Profound Research LLC	Carlsbad	California	92011	Withdrawn
University of California Irvine Medical Center	Irvine	California	92868	Recruiting
University of Colorado Neuromuscular Division	Aurora	Colorado	80045	Recruiting
SFM Clinical Research, LLC	Boca Raton	Florida	33487	Recruiting
Neuromuscular Research Division \| University of South Florida	Tampa	Florida	33612	Recruiting
Augusta University, Neuroscience Center	Augusta	Georgia	30912	Recruiting
NextGen Precision Health	Columbia	Missouri	65212	Recruiting
The University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	Recruiting
The Ohio State University	Columbus	Ohio	43221	Recruiting
University of Oregon	Portland	Oregon	97239	Recruiting
Semmes Murphey Clinic	Memphis	Tennessee	38120	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06414954, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06414954 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →